Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 23 (2), 180-190

Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus

Collaborators, Affiliations

Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus

Christopher G Fawsitt et al. Value Health.

Abstract

Objectives: Direct-acting antivirals containing nonstructural protein 5A (NS5A) inhibitors administered over 8 to 12 weeks are effective in ∼95% of patients with hepatitis C virus. Nevertheless, patients resistant to NS5A inhibitors have lower cure rates over 8 weeks (<85%); for these patients, 12 weeks of treatment produces cure rates greater than 95%. We evaluated the lifetime cost-effectiveness of testing for NS5A resistance at baseline and optimizing treatment duration accordingly in genotype 1 noncirrhotic treatment-naïve patients from the perspective of the UK National Health Service.

Methods: A decision-analytic model compared (1) standard 12-week treatment (no testing), (2) shortened 8-week treatment (no testing), and (3) baseline testing with 12-/8-week treatment for those with/without NS5A polymorphisms. Patients who failed first-line therapy were retreated for 12 weeks. Model inputs were derived from published studies. Costs, quality-adjusted life-years, and the probability of cost-effectiveness were calculated.

Results: Baseline testing had an incremental net monetary benefit (INMB) of £11 838 versus standard 12 weeks of therapy (no testing) and low probability (31%) of being the most cost-effective, assuming £30 000 willingness to pay. Shortened 8 weeks of treatment (no testing) had an INMB of £12 294 and the highest probability (69%) of being most cost-effective. Scenario analyses showed baseline testing generally had the highest INMB and probability of being most cost-effective if first- and second-line drug prices were low (<£20k).

Conclusions: Optimizing treatment duration based on NS5A polymorphisms for genotype 1 noncirrhotic treatment-naive patients in the United Kingdom is not cost-effective if the drug costs are high; the strategy is generally most cost-effective when drug prices are low (<£20k).

Keywords: baseline testing; cost-effectiveness; hepatitis C virus; resistance-associated polymorphisms.

Figures

Figure 1
Figure 1
One-way sensitivity analysis of NoTest8wks versus NoTest12wks.
Figure 2
Figure 2
One-way sensitivity analysis of Test12/8wks versus NoTest12wks.
Figure 3
Figure 3
Results on the (a) probability of cost-effectiveness and (b) expected incremental net monetary benefit versus 12 weeks (no testing) of various scenario analyses, at £30 000 willingness-to-pay: (i) different resistance test costs (assuming 80% reduction in drug costs) and (ii) different first-line cure rates in patients with NS5A resistance (assuming 80% reduction in drug costs).
Figure 4
Figure 4
Results of the probability of cost-effectiveness of differential percentage reductions in the cost of first-line treatment and retreatment, at £30 000 willingness-to-pay.

Similar articles

See all similar articles

References

    1. World Health Organization . World Health Organization; Paris, France: 2017. Global Hepatitis Report 2017.
    1. World Health Organization . World Health Organization; Geneva, Switzerland: 2016. Global Health Sector Strategy on Viral Hepatitis 2016-2021.
    1. Falade-Nwulia O., Suarez-Cuervo C., Nelson D.R., Fried M.W., Segal J.B., Sulkowski M.S. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166(9):637–648. - PMC - PubMed
    1. National Institute for Health and Care Excellence . National Institute for Health and Care Excellence; London, UK: 2015. Technology Appraisal Guidance [TA363]: Ledipasvir–Sofosbuvir for Treating Chronic Hepatitis C.
    1. Sarrazin C., Dvory-Sobol H., Svarovskaia E.S. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology. 2016;151(3):501–512.e501. - PubMed
Feedback